MEDIMMUNE RESPIGAM CANDIDATES IDENTIFIED BY PRUDENTIAL IN PULL-THROUGH PROGRAM; AVAILABLE RESPIGAM MEETS ONLY 40% OF DEMAND; FOLLOW-ON PRODUCT IN PHASE III
Prudential is identifying infants who fit labeling criteria for use of MedImmune's RespiGam and providing the names of their physicians to the company, MedImmune Director-Managed Care Stephen Collins told a Biotechnology Industry Organization meeting Feb. 11 in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth